NCT04755907

3D Bioprinted Models for Predicting Chemotherapy Response in Colorectal Cancer With/Without Liver Metastases

Status unknown Last updated 19 July 2022

What this trial tests

trial testing surgical resection in Colorectal Cancer in 120 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 March 2021
Primary completion	31 December 2022
Estimated completion	31 December 2023
Sites	4 locations across China

Drugs / interventions tested

• surgical resection
• adjuvant chemotherapy — full drug profile →
• neoadjuvant therapy — full drug profile →

Conditions studied

• Colorectal Cancer — all drugs for Colorectal Cancer →
• Colorectal Cancer Liver Metastasis — all drugs for Colorectal Cancer Liver Metastasis →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Colorectal Cancer or Colorectal Cancer Liver Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The therapeutic regimens of adjuvant and neoadjuvant chemotherapy for colorectal cancer (CRC) remain largely relied on clinical experience, and thus preclinical models are needed to guide individualized medicine. The investigators are going to establish 3D bioprinted CRC models and organoids from surgically resected tumor tissues of CRC patients with or without liver metastases. In vitro 3D models and organoids will be treated with the same chemotherapy drugs with the corresponding patients from whom the models are derived. The sensitivity of chemotherapy drugs will be tested in these two types of in vitro models, and the actual response to chemotherapy in patients will be evaluated. The predictive ability of 3D models for chemotherapy sensitivity in CRC patients will be compared with that of the organoids. This observational study will validate the potential value of 3D bioprinted tumor models in predicting the response to chemotherapy in CRC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.
   Letai A, Bhola P, Welm AL. · · 2022 · cited 182× · PMID 34951956 · DOI 10.1016/j.ccell.2021.12.004
2. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
   Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
3. Applications of human organoids in the personalized treatment for digestive diseases.
   Wang Q, Guo F, Jin Y, Ma Y. · · 2022 · cited 43× · PMID 36167824 · DOI 10.1038/s41392-022-01194-6
4. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
   Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
5. Engineered organoids for biomedical applications.
   Roberto de Barros N, Wang C, Maity S, Peirsman A, et al · · 2023 · cited 29× · PMID 37967768 · DOI 10.1016/j.addr.2023.115142
6. Micro-engineering and nano-engineering approaches to investigate tumour ecosystems.
   Kim M, Panagiotakopoulou M, Chen C, Ruiz SB, et al · · 2023 · cited 27× · PMID 37353679 · DOI 10.1038/s41568-023-00593-3
7. Prediction of Clinical Precision Chemotherapy by Patient-Derived 3D Bioprinting Models of Colorectal Cancer and Its Liver Metastases.
   Sun H, Sun L, Ke X, Liu L, et al · · 2024 · cited 25× · PMID 37973557 · DOI 10.1002/advs.202304460
8. Patient-derived cancer models: Valuable platforms for anticancer drug testing.
   Genta S, Coburn B, Cescon DW, Spreafico A. · · 2022 · cited 25× · PMID 36033445 · DOI 10.3389/fonc.2022.976065